News / Africa

Scientists Seek HIV Vaccine Using Monkey Model

 A red ribbon, the symbol of the worldwide campaign against AIDS. A red ribbon, the symbol of the worldwide campaign against AIDS.
x
 A red ribbon, the symbol of the worldwide campaign against AIDS.
A red ribbon, the symbol of the worldwide campaign against AIDS.

Multimedia

Audio
Joe DeCapua
Traditional vaccine methods have been unsuccessful in preventing infection by HIV, the virus that causes AIDS. New techniques are being studied to boost antibodies or other parts of the immune system. But researchers are also working on a method to keep the immune system constantly on guard against HIV.



There are two traditional methods for creating a vaccine. One uses a weakened or attenuated version of a live virus to generate an immune response. The other uses a dead virus. Both methods are proven safe and effective, except when it comes to HIV. Vaccine candidates using these methods simply have not been successful in people when it comes to the AIDS virus.

“HIV has been a very difficult target for a vaccine for a variety of reasons. It’s designed to evade the immune response by evolution,” said Dr. Louis Picker, associate director of Oregon Health and Science University.

While attempts to make an HIV vaccine from a dead virus have failed, Picker said, using a weakened virus holds clues and possibilities when used in primates.

“The live attenuated approach actually was shown to work 20 years ago. But the problem with it was the live attenuated vaccines that actually worked were actually still pathogenic. So they weren’t safe and they could not be moved into humans. This was demonstrated in the non-human primate models – monkey model of AIDS using the virus SIV,” he said.

SIV stands for simian immunodeficiency virus.

“These SIVs that were attenuated, that prevented subsequent infection with the full pathogenic virus, still could cause disease. And people found that if you attenuated them anymore, they didn’t work anymore,” he said.

Picker and his colleagues wanted to understand why the weakened virus offered protection from infection. But at the same time, they needed to prevent it from itself causing disease. They found the answer has to do with T cells, which attack viruses. The weakened, but persistent virus vaccines somehow caused T cells to be ever vigilant. But if the virus was weakened too much, the T cells were not triggered to attack. They concluded that an “effective HIV vaccine might have to persist in the body.”

Picker said, “The unique aspect of the live attenuated vaccines that seem to work was that they were persistent. They weren’t cleared by the host immune system, but they were able to stick around. Of course in the case of HIV/SIV that’s a bad thing, because eventually those live attenuated vaccines would gain strength and cause disease. But probably the fundamental reason, at least what I hypothesized, that they would be able to elicit protection was because of that persistence.”

So, they looked for another persistent virus that was not pathogenic, which might generate T cell immune response.

“The virus that we selected was a virus called cytomegalovirus (CMV), which is actually a virus from a different family of viruses altogether, but it’s one that most people in the world are infected with. But it’s unique in that you can re-infect these people with a virus that now has within its genes HIV genes and then the body would make immune responses to those HIV genes,” he said.

The HIV genes that would be placed in the harmless virus, he said, would not cause disease.

“When they’re introduced into the vaccinee, the immune response recognizes these HIV bits as if they’re part of CMV and raises immune response to it,” he said.

That’s the plan, anyway. The difficult part is making a version of the vaccine that’s safe and effective for humans. That requires an approved vaccine candidate and years of clinical trials.

Meanwhile, in Thailand, a follow-up study is getting underway of the RV 144 vaccine candidate. Several years ago, a study showed that it did indeed provide some measure of protection against HIV, but not enough, being only 31 percent effective.  A clinical study called RV 305 will use the same vaccine components as RV 144, but will attempt to boost and extend the immune response through antibodies.

You May Like

EU Court Fines Poland for Hosting CIA 'Black Sites'

Ruling is first time a court has acknowledged suspects were held and tortured at the sites, under US program launched following the 9/11 terrorist attacks More

Migrant Issues Close to Home Spur Groups to Take Action

Groups placing water, food in the desert, or aiding detainees after release, have one common goal: no more deaths of migrants crossing illegally into the US More

Video At AIDS Conference, Prevention Pill Stirs Excitement

Truveda shows promise, spurring debate over access and other approaches More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Treatment for Childhood Epilepsy Heats up Medical Marijuana Debatei
X
Shelley Schlender
July 24, 2014 6:43 PM
In the United States, marijuana is classed as an illegal drug by the federal government. But nearly half the states have legalized it, to some degree. Proponents say some strains of marijuana might have exceptional health benefits, for treating pain or inflammation in chronic conditions such as cancer, multiple sclerosis and epilepsy. Shelley Schlender reports on a strain of medical marijuana developed in Colorado that is reputed to reduce seizures in childhood epilepsy
Video

Video Treatment for Childhood Epilepsy Heats up Medical Marijuana Debate

In the United States, marijuana is classed as an illegal drug by the federal government. But nearly half the states have legalized it, to some degree. Proponents say some strains of marijuana might have exceptional health benefits, for treating pain or inflammation in chronic conditions such as cancer, multiple sclerosis and epilepsy. Shelley Schlender reports on a strain of medical marijuana developed in Colorado that is reputed to reduce seizures in childhood epilepsy
Video

Video Airbus Adds Metal 3D Printed Parts to New Jets

By the end of this year, European aircraft manufacturing consortium Airbus plans to deliver the first of its new, extra-wide-body passenger jets, the A350-XWB. Among other technological innovations, the new plane will also incorporate metal parts made in a 3-D printer. VOA's George Putic has more.
Video

Video Death Toll From Israel-Gaza Conflict Surpasses 700

Gaza officials say a shelling hit a compound housing a United Nations-run school in the Gaza Strip, killing more than a dozen people, during an Israeli offensive in the area. Heavy fighting between the Israeli military and Hamas militants continued on Thursday, pushing up the death toll. So far, more than 730 Palestinians and 35 Israelis have been killed in the conflict. VOA's Scott Bobb has the latest from Jerusalem.
Video

Video AIDS Conference Welcomes Exciting Developments in HIV Treatment, Prevention

Significant strides have been made in recent years toward the treatment and prevention of HIV, the virus that causes AIDS. This year, at the International AIDS Conference, the AIDS community welcomed progress on a new pill that may prevent transmission of the deadly virus. VOA’s Anita Powell reports from Melbourne, Australia.
Video

Video Israel Targets Gaza Supply Tunnels

The Israeli military has launched a ground operation in Gaza to destroy the myriad tunnels that may have been used to smuggle weapons to Hamas. VOA's Zlatica Hoke reports that could mean more hardship for the people of Gaza, who obtain some of their essential supplies through these underground passages
Video

Video Researchers Target Low-Cost Avatar Technology

Scientists at the University of Southern California Institute for Creative Technologies say 3-dimensional representations could revolutionize social media. Elizabeth Lee has more from Los Angeles.
Video

Video IAEA: Iran Turns its Enriched Uranium Into Less Harmful Form

Iran has converted its stockpiles of enriched uranium into a less dangerous form that is more difficult to use for nuclear weapons, according to the United Nations’ Atomic Energy Agency. The move complies with an interim deal reached with Western powers on Iran's nuclear program last year, in exchange for easing of sanctions. Henry Ridgwell reports for VOA from London.
Video

Video In Cambodia, HIV Diagnosis Brings Deadly Shame

Although HIV/AIDS is now a treatable condition, a positive diagnosis is still a life altering experience. In Cambodia, people living with HIV are often disowned by friends, family and the community. This humiliation can be unbearable. We bring you one Cambodian woman’s struggle to overcome a life tragedy and her own HIV positive diagnosis.

AppleAndroid